Velopalatine and Bilateral Vocal Cord Paralysis Associated with Atezolizumab Treatment: A Severe and Previously Undocumented Side Effect in Cancer Immunotherapy-Reference-Cited by-同舟云学术

Velopalatine and Bilateral Vocal Cord Paralysis Associated with Atezolizumab Treatment: A Severe and Previously Undocumented Side Effect in Cancer Immunotherapy

Published:2024-04-20 Issue:4 Volume:76 Page:3707-3709
ISSN:2231-3796
Container-title:Indian Journal of Otolaryngology and Head & Neck Surgery
language:en
Short-container-title:Indian J Otolaryngol Head Neck Surg

Author:

Lorente-Piera Joan,Zufiaurre Natalia Díaz,Fernández-González Secundino,Alcalde Juan

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s12070-024-04709-5.pdf

Reference5 articles.

1. Fountzilas E, Hiep Vo H, Mueller P, Kurzrock R, Tsimberidou AM (2023) Dataset of phase I and II immunotherapy clinical trials used for a meta-analysis to assess the role of biomarkers in treatment outcomes in diverse cancers. Data Brief 51:109698. https://doi.org/10.1016/j.dib.2023.109698

2. Willegers T, Janssen JBE, Boers-Sonderen MJ, Bekkers S (Apr 2020) Bilateral Vocal Cord Paralysis Due to an Immune-related Adverse Event of Nivolumab: A Case Report. Journal of Immunotherapy (Hagerstown, Md: 1997) 43(3):93–4. https://doi.org/10.1097/CJI.0000000000000310

3. Hamada S, Okamoto N, Tsukino M (2018) Bilateral vocal cord paralysis: Pembrolizumab-induced delayed-onset toxicity in a patient with lung adenocarcinoma. J Thorac Oncol. e257–9. https://doi.org/10.1016/j.jtho.2018.08.2032

4. Hartl DM, Ferté C, Loriot Y, Gomez Roca C, Bahleda R, Moldovan C, Mir O, Soria J-C (2010) Dysphonia induced by vascular endothelium growth factor/vascular endothelium growth factor receptor inhibitors. Invest New Drugs 28(6):884–886. https://doi.org/10.1007/s10637-009-9314-9

5. -Rhee JY, Torun N, Neilan TG, Guidon AC (2022) Consider myocarditis when patients treated with immune checkpoint inhibitors present with ocular symptoms. Oncologist 27:e402–e405. https://doi.org/10.1093/oncolo/oyac033